Taegeuk Sagye

Taegeuk Sagye, based in Gyeongsan, South Korea, specializes in the production and distribution of herbal health products, focusing on traditional Korean medicinal ingredients to enhance wellness and health. Taegeuk Sagye is dedicated to producing herbal health products leveraging traditional Korean medicinal ingredients. Founded in 2023, the company is headquartered in Gyeongsan, South Korea. Bo-hyeong Kim serves as both the CEO and founder of the company.

Taegeuk Sagye has secured one funding round, with the most recent deal taking place on February 3, 2026. Taegeuk Sagye specializes in the production and distribution of herbal health products, focusing on traditional Korean medicinal ingredients. Their offerings include various herbal supplements derived from local agricultural products, such as ginseng, wild vegetables, and medicinal herbs, cultivated in optimal growing conditions. The products aim to enhance health and wellness by providing natural solutions for respiratory health and immune support.

The clientele primarily consists of health-conscious consumers and local distributors across South Korea, Japan, the United States, and select European countries. The company engages directly with approximately 13 local farms to ensure high-quality raw materials and support local agriculture. Taegeuk Sagye generates revenue through a direct-to-consumer sales model, supplemented by partnerships with retailers and wholesalers. Revenue streams primarily come from herbal product sales, including premium ginseng and traditional herbal blends.

Pricing for these offerings ranges from 10,000 KRW to 180,000 KRW, depending on the type and quantity of ingredients. The company fosters customer relationships through promotional events and product sampling, encouraging repeat purchases and facilitating broader market accessibility for their flagship products. In February 2026, Taegeuk Sagye raised an undisclosed amount of venture funding from new investors Daejeon Creative Economy Innovation Center and People Investment. The funding will be used to secure talent, strengthen intellectual property, and advance core technologies.

The company plans to expand its product line with new herbal supplements aimed at respiratory and immune health by the end of 2026, alongside targeting new markets in Southeast Asia and Europe for increased distribution.